2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Non-Biological Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bleeding and Clotting, Platelet Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3847 A Phase 2b, multicenter, open-label, randomized, dose escalation, and dose optimization study of ofirnoflast (HT-6184) for the treatment of anemia in adults with very low- to intermediate-risk myelodysplastic syndromes requiring red blood cell transfusions: Trial in progress

Michael Jamie Hochman, MD, Hetty Carraway, MD, MBA2, Amy DeZern, MD, MHS3, Esther Natalie Oliva, MD4, Mikkael A. Sekeres, MD5, David Sallman, MD6, Amit Verma, MD7, Jeremiah Bearss, MD, PhD8, David Bearss, PhD9, Han Myint, MD, FRCP, FRCPath10, Alan F List, MD11
1 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Johns Hopkins University, Baltimore, Maryland, United States
4 London North West University Healthcare NHS Trust, London, United Kingdom
5 University of Miami Health System, Miami, Florida, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 Albert Einstein College of Medicine, Bronx, New York, United States
8 Halia Therapeutics, Lehi, Utah, United States
9 Halia Therapeutics, Lehi, Utah, United States
10 Halia Therapeutics, Lehi, Utah, United States
11 Halia Therapeutics, Lehi, Utah, United States

Background: NLRP3 inflammasome hyperactivation is a central pathogenic driver in lower-risk myelodysplastic syndrome (LR-MDS), promoting caspase-1-mediated IL-1β release, GATA-1 degradation, β-catenin activation, and pyroptosis of hematopoietic stem and progenitor cells, resulting in ineffective hematopoiesis. Ofirnoflast is a dual allosteric modulator of NIMA-related kinase 7 (NEK7)/NLRP3 assembly and myddosome signaling, providing a mechanistically distinct blockade of the entire NLRP3 inflammasome signaling pathway that extends from transcriptional priming to inflammasome complex assembly. Targeting this pathway therefore represents a rational therapeutic strategy in patients with transfusion-dependent anemia from LR-MDS, regardless of prior therapy (e.g., erythropoiesis-stimulating agents (ESAs), luspatercept, lenalidomide, or imetelstat), a population with a substantial unmet need. These patients remain dependent upon red blood cell (RBC) transfusions, which are associated with various complications including iron overload, reduced quality of life, and increased healthcare utilization. An effective oral agent would offer a meaningful therapeutic intervention in contrast to current parenteral therapies In a previous Phase 2a study, ofirnoflast was administered orally (PO) as a 2 mg capsule once daily (QD) for five days a week in patients with LR-MDS. This regimen resulted in 8-week RBC transfusion independence (TI) in 55.6% of patients who were RBC-transfusion-dependent (TD) (Bafna V et al., EHA 2026). This Phase 2b study (HT-6184-MDS-002) comprises two distinct phases: a dose-escalation phase and a dose-optimization phase using the ofirnoflast tablet formulation. These phases align with the FDA Project Optimus initiative to identify the optimal dose/regimen and further assess the safety and efficacy of ofirnoflast in RBC-TD LR-MDS patients.

Study Design and Arms: This multicenter, open-label, Phase 2b dose-escalation-optimization study will enroll approximately 65 participants at up to 38 sites in the United States. Enrollment will be divided into two phases: a dose-escalation phase (Part 1) and a parallel randomization enrollment phase (Part 2). In Part 1, approximately 25 participants will receive ofirnoflast at one of five doses: 1 mg, 1.5 mg, 2 mg, 2.5 mg, or 3 mg, PO QD using a BOIN design. Participants will be observed for a minimum of four weeks for acceptable safety and tolerability of the five dose levels. In Part 2, an additional 40 participants will be randomized 1:1 to one of the two selected doses based on safety and tolerability (total N=65).

Key eligibility criteria: Eligible participants must have MDS classified according to WHO 2022 criteria, a baseline IPSS-R score ≤4.5 and relapsed or refractory anemia after one to three lines of therapy for LR-MDS (excluding hypomethylating agents). Patients with myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and MDS/MPN overlap neoplasms are excluded. Participants must be TD, defined as receipt of ≥3 units of RBCs in at least two transfusion episodes during the 16 weeks immediately prior to randomization, with ≥2 units RBC administered during the preceding eight weeks. Endogenous serum erythropoietin (sEPO) level must be <500 U/L.

Treatment: Participants will receive ofirnoflast PO QD at their randomized dose for 24 weeks. Those deriving clinical benefit at Week 24 may enter an additional 24-week treatment extension period.

Endpoints: The primary endpoint is the selection of the optimal ofirnoflast daily dose for the Phase 3 study, as determined by the Dose Optimization/Selection Committee through an integrated assessment of (i) efficacy: Overall Response Rate (ORR) defined as the proportion of participants achieving RBC-TI for at least 16 consecutive weeks during Weeks 1-24 according to IWG 2018 criteria or CR/CReq+PR (IWG-2023 criteria); (ii) safety, including incidence and severity of treatment-emergent adverse events (TEAEs), dose modifications, and toxicity-related discontinuations; and (iii) pharmacokinetic exposure data. Secondary endpoints include safety and tolerability, durability of RBC-TI, and hematologic improvement. Exploratory assessments include patient-reported quality of life, biomarkers of inflammasome activity and pyroptosis, clonal expansion or regression, and pharmacokinetics.

Michael Jamie Hochman, MD: Doximity - Stock (publicly traded); Blueprint Medicines - Honoraria; Astellas Pharma - Honoraria; Rigel Pharmaceuticals - Honoraria; Daiichi-Sankyo - Honoraria; Taiho Oncology - Research Funding; Blueprint Medicines - Research Funding; Daiichi-Sankyo - Research Funding; Geron Corporation - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony)